13,109 results on '"Autoimmune hepatitis"'
Search Results
2. Belimumab in Autoimmune Hepatitis (BELief)
- Author
-
GlaxoSmithKline
- Published
- 2024
3. A Study on Factors of Biochemical Response in Autoimmune Hepatitis
- Author
-
Zhao Xinyan, Director, Principal Investigator, Clinical Professor
- Published
- 2024
4. TruGraf Liver Gene Expression Serial Test
- Author
-
Transplant Genomics, Inc.
- Published
- 2024
5. Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication (Nor-vaC)
- Author
-
University Hospital, Akershus and Guro Løvik Goll, Principal investigator
- Published
- 2024
6. Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients
- Author
-
Craig Lammert, Associate Professor of Medicine
- Published
- 2024
7. ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER)
- Published
- 2024
8. A-LiNK: Improving Outcomes in Autoimmune Liver Disease (ALINK)
- Published
- 2024
9. Distinct characteristics of various autoimmune liver diseases: A 22‐year hospital‐based study in Taiwan.
- Author
-
Chang, Ming‐Ling, Le, Puo‐Hsien, Chen, Wei‐Ting, Chen, Tai‐Di, Su, Chung‐Wei, Chen, Cheng‐Jen, Lin, Cheng‐Yu, Wu, Chi‐Huan, Kuo, Chia‐Jung, Sung, Kei‐Feng, and Chien, Rong‐Nan
- Subjects
- *
AUTOIMMUNE hepatitis , *STROKE , *SYSTEMIC lupus erythematosus , *HEPATITIS C virus , *VIRAL antibodies - Abstract
Background and Aim Methods Results Conclusions The characteristics of autoimmune liver diseases (AILDs), including primary biliary cholangitis (PBC), autoimmune hepatitis (AIH), and PBC‐AIH overlap syndrome (OS), have rarely been investigated and compared in Asia.At the Taiwan tertiary referral center, 330 PBC patients (87% treated with ursodeoxycholic acid [UDCA]), 143 AIH patients (94.4% treated with immunosuppressive therapy [IST]) and 21 PBC‐AIH OS patients (85.7% treated with UDCA and IST) were enrolled.Compared with AIH patients, PBC patients were older at baseline and had greater female‐to‐male sex ratios, alkaline phosphatase (ALP) and γ‐glutamyl transferase (γ‐GT) levels, and liver cirrhosis (LC), dyslipidemia, and hepatic and cardiometabolic complication rates. PBC patients had the lowest transaminase levels, whereas AIH patients had the highest transaminase levels. PBC patients had greater 22‐year all‐cause mortality and liver transplantation (ACMaLT) (43.5
vs 25.4%,P = 0.004), LC (75vs 58.5%,P < 0.01), dyslipidemia (54.4vs 45.9%,P = 0.001), and cerebrovascular accident (11.3vs 0.8%,P = 0.019) cumulative incidences (CIs) than did AIH patients; PBC‐AIH OS patients had greater systemic lupus erythematosus (28.9vs 8.9%,P = 0.009) CI than did PBC patients. Baseline ALP (hazard ratio: 1.001), albumin (0.514), platelet count (0.997), and LC (3.438) were associated with ACMaLT; age (1.110), albumin (0.350), cirrhosis (46.219), and hepatitis C virus antibody positivity (5.068) were associated with hepatocellular carcinoma (HCC); and female sex (2.183) and body mass index (1.054) were associated with autoimmune diseases.Compared with AIH patients, PBC patients had greater cardiometabolic CI, and ACMaLT CI, which was associated with cholestasis, liver functional reserve and LC. Older AILD patients with LC and females with obesity demand special caution for the development of HCC and extrahepatic autoimmune diseases, respectively. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
10. Evaluation of Noninvasive Tools for Predicting Esophageal Varices in Patients With Cirrhosis at Tygerberg Hospital, Cape Town.
- Author
-
Kwape, Lawrence, Gabriel, Shiraaz, Abdelsalem, Ahmad, Rose, Penelope, Bathobakae, Lefika, Peterson, Dale, Moodley, Desiree, Parker, Mohammed, Moolla, Saadiq, Parker, Arifa, Siamisang, Keatlaretse, Van Rensburg, Christoffel, Fredericks, Ernst, and Uhlmann, Dirk
- Subjects
- *
AUTOIMMUNE hepatitis , *ESOPHAGEAL varices , *HEPATITIS B virus , *PORTAL hypertension , *PORTAL vein , *ACOUSTIC radiation force impulse imaging - Abstract
Background: In patients with cirrhosis, esophageal variceal hemorrhage (EVH) is a devastating consequence of portal hypertension (PH). Upper endoscopy is considered the gold standard for the detection and diagnosis of esophageal varices (EVs), despite being invasive and costly. This study was aimed at identifying and evaluating the diagnostic accuracy of noninvasive tools in predicting EVs in patients with compensated cirrhosis. Methods: This cross‐sectional study included 50 patients with compensated cirrhosis at the Tygerberg Hospital Gastroenterology Clinic in Cape Town between November 2022 and May 2023. We collected clinical, anthropometric, and laboratory data from patients' physical and electronic charts. All patients underwent an abdominal ultrasound, vibration‐controlled transient elastography (VCTE) to assess liver and splenic stiffness, and upper endoscopy. In this comparative study, we evaluated the diagnostic accuracy of different noninvasive tools in detecting EVs in patients with compensated cirrhosis. Results: Of the 50 patients included in the study, 30 (60%) were female and 20 (40%) were male. The patients' age ranged from 18 to 83, with a mean age of 46.6 years. Cirrhosis was mainly due to alcohol use (n = 11, 22%), hepatitis B virus (HBV) infection (n = 11, 22%), and autoimmune hepatitis (n = 10, 20%). The patients included in the study were divided into two subgroups: with (n = 34, 68%) or without (n = 16, 32%) EVs. Statistically significant differences were detected between groups in platelet count (PC), liver stiffness measurement (LSM), spleen stiffness measurement (SSM), portal vein diameter (PVD), bipolar spleen diameter (SBD), aspartate aminotransferase‐to‐platelet ratio index (APRI), fibrosis‐4 index (FIB‐4), platelet/bipolar spleen diameter ratio (PSR), liver stiffness‐spleen size‐platelet ratio (LSPS), liver stiffness‐spleen stiffness‐platelet ratio score (LS3PS), and spleen stiffness‐spleen size‐platelet ratio score (SSPS) (p < 0.001). The highest diagnostic precision was observed with SSM (96%), SSPS (96%), LS3PS (94%), LSPS (94%), PSR (94%), and PC (92%). SBD (88%), LSM (86%), APRI (82%), and FIB‐4 (82%) had the lowest diagnostic accuracy. Conclusion: SSM and SSPS have the highest diagnostic accuracy for predicting the presence of EVs in patients with compensated cirrhosis. LSPS, LS3PS, and PSR come second at 94%. We recommend SSM and SSPS in institutions with transient elastography equipped with the software necessary to measure splenic stiffness. We introduce and propose LS3PS as a novel composite score for predicting the presence of EVs in patients with compensated cirrhosis. Large‐sample‐size studies are needed to validate these prediction scores and to allow direct comparison with Baveno VII. These prediction tools can help clinicians avoid unnecessary endoscopic procedures in patients with compensated cirrhosis, especially in developing countries with limited resources such as South Africa. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Waitlist and transplant outcomes in patients with metabolic dysfunction‐associated steatotic liver disease and autoimmune hepatitis.
- Author
-
Medina‐Morales, Esli, Ismail, Mohamed, Goyal, Ritik M., Marenco‐Flores, Ana, Saberi, Behnam, Fricker, Zachary, Bonder, Alan, and Trivedi, Hirsh D.
- Subjects
- *
FATTY liver , *AUTOIMMUNE hepatitis , *LIVER diseases , *LIVER transplantation , *TREATMENT effectiveness - Abstract
Background and Aims Methods Results Conclusions Metabolic dysfunction‐associated steatotic liver disease (MASLD), in the context of autoimmune hepatitis (AIH) among liver transplantation (LT) candidates or recipients remains poorly understood. This study compares waitlist and post‐LT outcomes in patients with MASLD/AIH to MASLD and AIH alone.Using the united network organ sharing database (2002–2022), we compared waitlist outcomes and post‐LT survival among patients with MASLD/AIH (n = 282), AIH (n = 5812), and MASLD (n = 33 331). Competing risk, Kaplan Meier estimates and Cox proportional hazard analyses were performed.MASLD/AIH group had the highest rates of encephalopathy and ascites, and highest MELD scores. MASLD/AIH patients had higher transplantation incidence (adjusted subdistribution hazard ratio [aSHR] 1.64, 95% CI 1.44–1.85; p < .001) and lower waitlist removal risk (aSHR .30, 95% CI .20–.44; p < .001) compared to MASLD alone. One‐year post‐LT survival favoured MASLD compared to AIH (patient: 92% vs. 91%, p < .001; graft: 89% vs. 88%, p < .001) and MASLD/AIH (patient: 92% vs. 90%, p = .008; graft: 89% vs. 88%, p = .023). Recipients with MASLD/AIH showed no significant difference in survival at 10‐year post‐LT compared to MASLD (patient: 63% vs. 61%, p = .68; graft 60% vs. 59%, p = .83) and AIH (patient: 63% vs. 70%, p = .07; graft: 60% vs. 64%, p = .42).Our study showed that MASLD/AIH patients demonstrate higher LT incidence and lower dropout rates. Long‐term post‐LT outcomes did not significantly differ between groups. Further prospective multicenter studies are needed to validate these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Role of liver biopsy in the management of idiosyncratic DILI.
- Author
-
Kleiner, David E.
- Subjects
- *
AUTOIMMUNE hepatitis , *LIVER biopsy , *BILE ducts , *DIAGNOSIS , *LIVER injuries - Abstract
Drug‐induced liver injury (DILI) presents unique challenges in clinical practice. While some types of DILI are mild and resolve quickly after removing the drug, other situations are more complex, with competing aetiologies or underlying liver disease. Guidelines from professional societies agree that the liver biopsy retains a role in understanding and managing DILI in certain situations. Liver biopsy allows characterization of the histological pattern of injury as well as assessment of severity. Inflammatory infiltrates, bile duct injury or loss and vascular injury are all revealed by liver biopsy. Communication between the hepatopathologist and clinical team with clinicopathological correlation of the findings is necessary for the best determination of causality and differentiation from other diseases of exclusion, like autoimmune hepatitis and graft‐versus‐host disease. This review highlights important aspects of the role of liver biopsy in DILI evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis.
- Author
-
Singleton, Carolyn, Carter, Allie, Baker, Brittany, Jones, Emma, Green, Kelsey, Lammert, Craig, and Nephew, Lauren D.
- Subjects
- *
AUTOIMMUNE hepatitis , *SYSTEMIC lupus erythematosus , *INCOME , *MEDICAL personnel , *LOGISTIC regression analysis - Abstract
Summary Background and Aims Methods Results Conclusion Diminished quality of life has been well characterized in patients with autoimmune hepatitis (AIH); however, the full spectrum of unmet needs is unclear. We hypothesized that there is a high burden of health‐related unmet needs in patients with AIH, and this burden differs by socioeconomic status (SES).Members of the Autoimmune Hepatitis Association were invited online and by email to complete a modified version of the Systemic Lupus Erythematosus Patient Needs Questionnaire. Demographic and clinical data were also captured. Low SES was defined as annual household income <30 k, education level below high school, or moderate–high concern for transportation, food or housing. Multivariable logistic regression assessed the association between unmet health‐related needs and SES.There were 433 participants; 89.8% identified as women, 16.2% lived outside the US, and 25.6% were classified as low SES. Over 70% of respondents reported at least one moderate–high need in the health‐related unmet need domains. In multivariable logistic regression, patients in the low‐SES group reported significantly higher odds of unmet needs compared to the moderate–high‐SES group: for adequate information about side effects (OR 1.64, 95% CI 1.06–2.53, p = 0.026), opportunity to speak with others with AIH (OR 2.34, 95% CI 1.50–3.66, p < 0.001), healthcare professionals acknowledging patient emotions (OR 2.41, 95% CI 1.56–3.74, p < 0.001) and being taken seriously by medical providers (OR 2.09, 95% CI 1.34–3.28, p = 0.001).There is a high burden of health‐related unmet needs in all patients with AIH that is exacerbated by low SES. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Etiology-Specific Effects of Impaired Functional Status on Liver Transplant Outcomes.
- Author
-
Lee, David Uihwan, Bhowmick, Kuntal, Althwanay, Aldanah, Sandlow, Sarah, Wiseman, Michal, Lee, Ki Jung, Fan, Gregory Hongyuan, Chou, Hannah, Chou, Harrison, Schuster, Kimberly, Lee, KeeSeok, and Lominadze, Zurabi
- Subjects
- *
KARNOFSKY Performance Status , *AUTOIMMUNE hepatitis , *ETIOLOGY of diseases , *HEPATITIS B , *GENETIC disorders - Abstract
Background and Aims: Pre-liver transplant (LT) functional status is an important determinant of prognosis post LT. There is insufficient data on how functional status affects outcomes of transplant recipients based on the specific etiology of liver disease. We stratified LT recipients by etiology of liver disease to evaluate the effects of functional status on post-LT prognosis in each subgroup. Methods: 2005–2019 United Network for Organ Sharing (UNOS) Standard Transplant Analysis and Research (STAR) was used to select patients with liver transplant. A total of 14,290 patients were included in the analysis. These patients were stratified by functional status according to Karnofsky Performance Scale (KPS) score: no assistance, some assistance, or total assistance. They were then further divided into six diagnosis categories: metabolic dysfunction-associated steatotic liver disease (MASLD), hereditary disorders, hepatitis C, hepatitis B, autoimmune disease (AID), and alcoholic liver disease (ALD). Primary endpoints included all-cause mortality and graft failure, while secondary endpoints included organ-specific causes of death. Those under the age of 18 and those with non-whole liver or prior liver transplantation were excluded. Results: Patients with MASLD requiring some assistance (aHR: 1.57, 95% CI 1.03–2.39, p = 0.04) and those requiring total assistance (aHR: 2.32, 95% CI 1.48–3.64, p < 0.001) had higher incidences of graft failure compared to those requiring no assistance. Those with MASLD requiring total assistance had a higher all-cause mortality rate than those needing no assistance (aHR: 1.62, 95% CI 1.38–1.89, p < 0.001). Patients with hereditary causes of liver disease showed a lower incidence of all-cause mortality in recipients needing some assistance compared with those needing no assistance (aHR: 0.52, 95% CI 0.34–0.80, p = 0.003). LT recipients with hepatitis C, AID, and ALD all showed higher incidences of all-cause mortality in the total assistance cohort when compared to the no assistance cohort. For the secondary endpoints of specific cause of death, transplant recipients with MASLD needing total assistance had higher rates of death due to general cardiac causes, graft rejection, general infectious causes, sepsis, general renal causes, and general respiratory causes. Conclusion: Patients with MASLD cirrhosis demonstrated the worst overall outcomes, suggesting that this population may be particularly vulnerable. Poor functional status in patients with end-stage liver disease from hepatitis B or hereditary disease was not associated with a significantly increased rate of adverse outcomes, suggesting that the KPS score may not be broadly applicable to all patients awaiting LT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Evaluation of a Ten-Antigen Immunodot Test in Autoimmune Hepatitis and Primary Biliary Cholangitis: Lessons Learned for a Tertiary Care Academic Hospital.
- Author
-
Zorzi, Giulia, Pokem, Perrin Ngougni, Dahlqvist, Geraldine, Délire, Bénédicte, Lanthier, Nicolas, Starkel, Peter, Horsmans, Yves, Aupaix, Cedric, Jnaoui, Samia, and Gruson, Damien
- Subjects
- *
BILIOUS diseases & biliousness , *AUTOIMMUNE hepatitis , *ENZYME-linked immunosorbent assay , *LIVER diseases , *AUTOIMMUNE diseases , *CHOLANGITIS - Abstract
Autoimmune diseases of the liver and biliary tract require timely and accurate diagnosis. This study evaluates the D-tek panel (D-Tek, Mons, Belgium) of 10 immunodot antigens for its effectiveness in diagnosing autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). We retrospectively analysed serum samples from 111 patients who had undergone routine testing, including indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISA), to confirm or exclude autoimmune liver or biliary tract disease. The panel tested for M2/nPDC, M2/OGDC-E2, M2/BCOADC-E2, M2/PDC-E2, gp210, sp100, LKM1, LC1, SLA, and F-actin antigens. Results showed that all positive IIF+ELISA results were confirmed by the immunodot panel, except for two samples from patients who had never been diagnosed with AIH. The immunodot test identified over 20 additional autoantibodies in samples initially negative by IIF, corroborated by laboratory imaging and medical history. The immunodot technique proved to be a quick, sensitive, and specific method with high overall accuracy. This study suggests that the immunodot technique may be an effective screening and confirmatory method for autoimmune liver diseases, potentially improving diagnostic efficiency and accuracy in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Easy recognition and high autoimmune hepatitis specificity of smooth muscle antibodies giving an actin microfilament immunofluorescent pattern on embryonal vascular smooth muscle cells.
- Author
-
Granito, Alessandro, Muratori, Paolo, Pappas, Georgios, Lenzi, Marco, Czaja, Albert J, and Muratori, Luigi
- Subjects
- *
VASCULAR smooth muscle , *FATTY liver , *AUTOIMMUNE hepatitis , *CHRONIC active hepatitis , *CYTOPLASMIC filaments - Abstract
Smooth muscle antibodies (SMA) with anti-microfilament actin (MF-SMA) specificity are regarded as highly specific markers of type 1 autoimmune hepatitis (AIH-1) but their recognition relying on immunofluorescence of vessel, glomeruli, and tubules (SMA-VGT pattern) in rodent kidney tissue, is restricted by operator-dependent interpretation. A gold standard method for their identification is not available. We assessed and compared the diagnostic accuracy for AIH-1 of an embryonal aorta vascular smooth muscle (VSM) cell line-based assay with those of the rodent tissue-based assay for the detection of MF-SMA pattern in AIH-1 patients and controls. Sera from 138 AIH-1 patients and 295 controls (105 primary biliary cholangitis, 40 primary sclerosing cholangitis, 50 chronic viral hepatitis, 20 alcohol-related liver disease, 40 steatotic liver disease, and 40 healthy controls) were assayed for MF-SMA and SMA-VGT using VSM-based and rodent tissue-based assays, respectively. MF-SMA and SMA-VGT were found in 96 (70%) and 87 (63%) AIH-1 patients, and 2 controls (P < 0.0001). Compared with SMA-VGT, MF-SMA showed similar specificity (99%), higher sensitivity (70% vs 63%, P = ns) and likelihood ratio for a positive test (70 vs 65). Nine (7%) AIH-1 patients were MF-SMA positive despite being SMA-VGT negative. Overall agreement between SMA-VGT and MF-SMA was 87% (kappa coefficient 0.870, [0.789–0.952]). MF-SMA were associated with higher serum γ‐globulin [26 (12–55) vs 20 g/l (13–34), P < 0.005] and immunoglobulin G (IgG) levels [3155 (1296–7344) vs 2050 mg/dl (1377–3357), P < 0.002]. The easily recognizable IFL MF-SMA pattern on VSM cells strongly correlated with SMA-VGT and has an equally high specificity for AIH-1. Confirmation of these results in other laboratories would support the clinical application of the VSM cell-based assay for reliable detection of AIH-specific SMA. (i) The search for smooth muscle antibodies (SMA) is a cornerstone of hepatic autoimmune serology, being one of the diagnostic criteria of autoimmune hepatitis (AIH). (ii) SMA are directed against structures of the cytoskeleton such as microfilaments, intermediate filaments, and microtubules. Although they may be detected in sera of patients with viral hepatitis, drug-induced hepatitis, and alcohol-related and non-alcohol-related fatty liver disease, SMA directed against actin microfilaments (MF-SMA) are highly AIH-specific. (iii) The recommended rodent tissue-based IFL for detecting MF-SMA is somewhat complicated, and the interpretation of the results depends on the operator's experience. The use of an embryonal aorta vascular smooth muscle cell line-based IFL assay provides high accuracy and easy detection of MF-SMA, the most AIH-specific SMA. Graphical Abstract [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Diagnostic features of autoimmune hepatitis in SARS-CoV-2-vaccinated vs. unvaccinated individuals.
- Author
-
AKIFUMI KUWANO, SHIGEHIRO NAGASAWA, YUTA KOGA, KOSUKE TANAKA, MASAYOSHI YADA, AKIHIDE MASUMOTO, and KENTA MOTOMURA
- Subjects
- *
CHRONIC active hepatitis , *SARS-CoV-2 , *AUTOIMMUNE hepatitis , *COVID-19 , *VACCINATION status , *COVID-19 pandemic - Abstract
The global coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected millions of lives, leading to significant morbidity and mortality. With >772 million cases and nearly seven million deaths reported worldwide to date, the development of vaccines has been a critical step in mitigating the impact of COVID-19. However, concerns have arisen regarding the potential for SARS-CoV-2 mRNA vaccination to trigger autoimmune diseases, including autoimmune hepatitis (AIH). The present single-center, retrospective study aimed to compare the clinical and pathological features of AIH in patients with or without a history of SARS-CoV-2 mRNA vaccination. A total of 72 patients with AIH were examined. Among them, 10 had received the SARS-CoV-2 mRNA vaccination prior to AIH onset. These patients exhibited more pronounced CD4+ T cell infiltration into the liver tissue compared with those who were unvaccinated. No significant differences in the levels of other liver enzymes, autoimmune antibodies, or CD8+ T cell infiltration were observed between the groups. Moreover, the AIH patients with a history of SARS-CoV-2 mRNA vaccination had more extensive CD4+ T cell infiltration in their liver tissues than the unvaccinated patients. These findings suggested that the immune response to SARS-CoV-2 mRNA vaccination may influence the pathogenesis of AIH, highlighting the need for further research into the relationship between SARS-CoV-2 mRNA vaccination and autoimmune liver diseases. Such studies will also help clarify the distinction between vaccine-induced liver injury and traditional AIH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Evolving trends and outcomes on the US liver transplant waitlist of alcohol‐associated hepatitis patients with very high MELD scores.
- Author
-
Tanaka, Tomohiro and Axelrod, David
- Subjects
- *
COVID-19 pandemic , *FATTY liver , *AUTOIMMUNE hepatitis , *LIVER diseases , *LIVER transplantation , *CHOLANGITIS - Abstract
Liver transplantation (LT) in patients with alcohol‐associated hepatitis (AH) has rapidly increased following the coronavirus disease 2019 pandemic and the implementation of the Acuity Circle policy, raising questions of equity and utility. Waitlist mortality among high (≥37) Model for End‐Stage Liver Disease LT candidates with AH and post‐transplant survival were assessed with a semiparametric survival regression and a generalized linear mixed‐effect model with LT centre‐ and listing date‐level random intercepts. These models demonstrate a lower mortality for the candidates listed with AH (adjusted sub‐hazard ratio.58_.72_.90 and odds ratio.44_.66_.99) when compared to other diagnoses (autoimmune hepatitis, metabolic dysfunction‐associated fatty liver disease and primary biliary cholangitis). Post‐LT survival was comparable. This study highlights the limitations of current tools in characterizing the risk of mortality, and thus need for the modifications in prioritizing LT candidates with AH. Policy revision may be needed to ensure equivalent access to LT regardless of diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry.
- Author
-
Riveiro‐Barciela, Mar, Barreira‐Díaz, Ana, Esteban, Paula, Rota, Rosa, Álvarez‐Navascúes, Carmen, Pérez‐Medrano, Indhira, Mateos, Beatriz, Gómez, Elena, De‐la‐Cruz, Gema, Ferre‐Aracil, Carlos, Horta, Diana, Díaz‐González, Álvaro, Ampuero, Javier, Díaz‐Fontenla, Fernando, Salcedo, Magdalena, Ruiz‐Cobo, Juan‐Carlos, and Londoño, María‐Carlota
- Subjects
- *
AUTOIMMUNE hepatitis , *AUTOIMMUNE diseases , *LIVER failure , *CIRRHOSIS of the liver , *RITUXIMAB - Abstract
Background and Aims: Small series suggest that rituximab could be effective as treatment for autoimmune hepatitis (AIH), although data are scarce. We aimed to evaluate the efficacy and safety of rituximab in different cohorts of patients with AIH. Methods: Multicentre retrospective analysis of the 35 patients with AIH and its variant forms treated with rituximab and included in the ColHai registry between 2015 and 2023. Results: Most patients were female (83%), 10 (29%) had cirrhosis and four (11.4%) variant forms of AIH. Indication for rituximab were as follows: 14(40%) refractory AIH, 19(54%) concomitant autoimmune or haematological disorder, 2(6%) intolerance to prior treatments. In three (9%) subjects with a concomitant disorder, rituximab was the first therapy for AIH. Overall, 31 (89%) patients achieved or maintained complete biochemical response (CBR), including the three in first‐line therapy. No difference in CBR was observed according to rituximab indication (refractory AIH 86% vs. concomitant disorders 90%, p =.824) or cirrhosis (80% vs. 92%, p =.319). Rituximab was associated with a significant reduction in corticosteroids (median dose: prior 20 vs. post 5 mg, p <.001) and the discontinuation of ≥1 immunosuppressant in 47% of patients. Flare‐free rate at 1st, 2nd and 3rd year was 86%, 73% and 62% respectively. Flares were not associated with the development of liver failure and were successfully managed with repeated doses of rituximab and/or increased corticosteroids. Three (9%) patients experienced infusion‐related adverse events (1 anaphylaxis and 2 flu‐like symptoms) and five (14%) infections. Conclusion: Rituximab is safe and effective in patients with refractory AIH and those treated due to concomitant autoimmune or haematological disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. IAIH‐PG consensus for histological criteria of AIH: Multicentre validation with focus on chronic liver diseases in China.
- Author
-
Wang, Li, Du, Zhi‐Xiang, Liu, Hong‐Li, Zhang, Yu, Wang, Shuang‐Shuang, Hu, Yi‐Fan, Li, Li‐Qiu, Zhu, Ping, Zhong, Yan‐Dan, Xiong, Qing‐Fang, and Yang, Yong‐Feng
- Subjects
- *
AUTOIMMUNE hepatitis , *SYMPTOMS , *CHINESE people , *LIVER diseases , *CHRONICALLY ill - Abstract
Background and Aims: The International AIH Pathology Group (IAIH‐PG) put forward the new histological criteria of autoimmune hepatitis (AIH) in 2022, which have not undergone adequate verification. In this study, we verified the applicability of the new histological criteria in the population of Chinese patients with chronic liver disease, comparing it with the simplified criteria. Methods: The gold standard for diagnosis in all patients was based on histological findings, combined with clinical manifestations and laboratory tests and determined after a follow‐up period of at least 3 years. A total of 640 patients with various chronic liver diseases from multiple centres underwent scoring using the new histological criteria and the simplified criteria, comparing their diagnostic performance. Results: In this study, the new histological criteria showed a sensitivity of 73.6% and 100% for likely and possible AIH, with specificities of 100% and 69.0% respectively. The coincidence rates of possible AIH for the new histological criteria, simplified histological criteria and simplified score were 81.7%, 72.8% and 69.7% respectively. For likely AIH, the rates were 89.2%, 75.9% and 65.6% respectively. Based on the new histological criteria, all patients with AIH were correctly diagnosed. Specifically, 73.6% were diagnosed with likely AIH and 26.4% were possible AIH. Additionally, the simplified histological criteria achieved a diagnosis rate of 98.6% for AIH, while the simplified score could only diagnose 53.8% of AIH. Conclusions: Compared with the simplified score and simplified histological criteria, the sensitivity and specificity of the new histological criteria for AIH were significantly improved. The results indicate that the new histological criteria exhibit high sensitivity and specificity for diagnosing AIH in China. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Homotherapy for heteropathy: Interleukin‐41 and its biological functions.
- Author
-
Shi, Runfeng, He, Meixin, Peng, Yongzheng, and Xia, Xu
- Subjects
- *
IMMUNOLOGIC diseases , *CROHN'S disease , *AUTOIMMUNE hepatitis , *THERAPEUTICS , *RESPIRATORY diseases - Abstract
Interleukin‐41 (IL‐41) is a newly discovered cytokine, named Cometin, Subfatin, meteorin‐like transcription (Metrnl), and so forth. It is widely expressed in animals and can exert its biological roles through autocrine and paracrine forms. It has functions such as anti‐inflammatory, improving body metabolism, regulating immunity, regulating fat metabolism and participates in the process of autoimmune disease or inflammatory injury. It plays an important role in psoriasis, diabetes, Crohn's disease (CD), osteoarthritis, Kawasaki disease (KD), Graves' disease, autoimmune hepatitis, infertility, obesity, sepsis, cardiovascular diseases and respiratory diseases. This paper reviews the biological functions of IL‐41, the relationship between IL‐41 and diseases, the effects of IL‐41 in the cytokine network and the possible signalling pathways. In order to explore the same target or the same drug for the treatment of different diseases from the perspective of homotherapy for heteropathy, cytokine strategies based on IL‐41 have been put forward for the precise treatment of immune diseases and inflammatory diseases. It is worth noting that IL‐41 related preparations for lung protection and smoking cessation are interesting research fields. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. AIH Therapy: Beyond First-Line.
- Author
-
Adao, Irina, Klepper, Arielle, and Tana, Michele
- Abstract
Purpose of Review: The purpose of the article is to review treatment options for patients with AIH for whom first-line therapy is not successful. We outline recommended approaches for providers and new therapies on the horizon. Recent Findings: Budesonide, while advantageous in some respects, may not be as effective as predniso(lo)ne. Mycophenolate mofetil is most effective in the setting of azathioprine intolerance and less effective when the response to azathioprine has been inadequate. Infliximab is the biologic agent with the most evidence for use in AIH. Clinical trials studying interleukin 2, regulatory T cells, inhibitors of BAFF signaling, and immunoproteasome inhibitors have been initiated but more research is needed, particularly in Black people, Indigenous people, and People of Color. Summary: While multiple agents have been reported as second- or third-line therapies, the evidence is limited. Future research will require multicenter collaboration and should explore therapeutics supported by molecular studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Isolated primary CNS lymphoma after liver transplantation for autoimmune hepatitis: a case report.
- Author
-
Zayed, Alaa, Abdoh, Qusay, Sarama, Asmaa, and Shubietah, Abdalhakim
- Subjects
- *
AUTOIMMUNE hepatitis , *LYMPHOPROLIFERATIVE disorders , *LIVER transplantation , *CENTRAL nervous system , *BRAIN damage - Abstract
Post-transplantation primary central nervous system lymphoma (PT-PCNSL) is a rare neoplasm that occurs in immunocompromised patients. It can manifest months or years after transplantation, presenting with various neurological symptoms. A 64-year-old woman, who had received a liver transplant due to autoimmune hepatitis, presented with generalized weakness, headache, and confusion. Further investigation revealed multiple ring-enhancing lesions in the right frontal and temporoparietal regions on brain MRI. A brain biopsy confirmed the diagnosis of PT-PCNSL. This case underscores the importance of considering PT-PCNSL in the differential diagnosis of contrast-enhancing brain lesions in post-transplant patients. Timely recognition of PT-PCNSL is crucial for appropriate management and improved outcomes. To the best of our knowledge, this report describes the first instance of isolated CNS lymphoma in a liver transplant recipient, due to autoimmune hepatitis, successfully brought to complete remission with a rituximab-methotrexate regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Acute liver failure.
- Author
-
Maiwall, Rakhi, Kulkarni, Anand V, Arab, Juan Pablo, and Piano, Salvatore
- Subjects
- *
HEPATIC encephalopathy , *AUTOIMMUNE hepatitis , *LIVER failure , *PLASMA exchange (Therapeutics) , *ANTITUBERCULAR agents - Abstract
Acute liver failure (ALF) is a life-threatening disorder characterised by rapid deterioration of liver function, coagulopathy, and hepatic encephalopathy in the absence of pre-existing liver disease. The cause of ALF varies across the world. Common causes of ALF in adults include drug toxicity, hepatotropic and non-hepatotropic viruses, herbal and dietary supplements, antituberculosis drugs, and autoimmune hepatitis. The cause of liver failure affects the management and prognosis, and therefore extensive investigation for cause is strongly suggested. Sepsis with multiorgan failure and cerebral oedema remain the leading causes of death in patients with ALF and early identification and appropriate management can alter the course of ALF. Liver transplantation is the best current therapy, although the role of artificial liver support systems, particularly therapeutic plasma exchange, can be useful for patients with ALF, especially in non-transplant centres. In this Seminar, we discuss the cause, prognostic models, and management of ALF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Evaluation of autoimmune liver disease antibodies in hepatitis patients.
- Author
-
Kim, Namsoo, Kim, Sinyoung, Choi, Jong Rak, and Park, Younhee
- Subjects
- *
AUTOIMMUNE hepatitis , *IMMUNOGLOBULIN G , *ANTINUCLEAR factors , *ANTIBODY titer , *IMMUNOASSAY - Abstract
Background/aims: Autoimmune hepatitis (AIH) is characterized by the presence of auto-antibodies and high blood immunoglobulin G (IgG) levels. In this study, the line immunoassay (LIA) was designed to assess various autoantibodies. Methods: In total, 1371 patients who underwent autoimmune liver disease antibody testing between July 2019 and November 2022 were enrolled. Autoantibodies including antinuclear antibody (ANA) and anti-mitochondrial antibody (AMA) were tested, and clinical data were collected. Statistical analyses were performed by categorizing the data based on diagnosis and IgG quantification separately. A scoring system was applied to identify individuals with AIH. Patients were also classified into the AIH and non-AIH groups. Results: The positivity rate for ANA was 80.2% in the AIH group. The IgG-high group had a high likelihood of the presence of detectable autoantibodies, with anti-Ro-52 being the most frequently detected antibody using LIA. The "Consider AIH" and "AMA" groups had 3–4 times more patients in the IgG-high group than in the "Not Considered" group. Conclusions: Among autoantibodies, the prevalence of ANA was the highest. As per LIA results, anti-Ro-52 was the most prevalent. AIH cannot be diagnosed based on IgG levels alone and must be distinguished via autoantibody testing. Therefore, extensive testing, including autoantibodies, IgG, ANA, and liver enzyme levels, will help accurately diagnose AIH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Astaxanthin Alleviates Autoimmune Hepatitis by Modulating CD8+ T Cells: Insights From Mass Cytometry and Single‐Cell RNA Sequencing Analyses.
- Author
-
He, Yuting, Ding, Mingjie, Zhang, Jiakai, Huang, Changjun, Shi, Jihua, Wang, Yun, Tao, Ruolin, Wu, Zeyu, and Guo, Wenzhi
- Subjects
- *
RNA sequencing , *AUTOIMMUNE hepatitis , *T cells , *CELL physiology , *TRANSCRIPTION factors , *ASTAXANTHIN - Abstract
Astaxanthin (ASX) is an oxygen‐containing non‐vitamin A carotenoid pigment. However, the role of ASX in autoimmune hepatitis (AIH) remains unclear. In this study, a mouse model of AIH is established induced by concanavalin A (ConA). Mass cytometry and single‐cell RNA sequencing (scRNA‐seq) are used to analyze the potential role of ASX in regulating the immune microenvironment of AIH. ASX treatment effectively alleviated liver damage induced by ConA and downregulated pro‐inflammatory cytokines production in mice. Mass cytometry and scRNA‐seq analyses revealed a significant increase in the number of CD8+ T cells following ASX treatment. Functional markers of CD8+ T cells, such as CD69, MHC II, and PD‐1, are significantly downregulated. Additionally, specific CD8+ T cell subclusters (subclusters 4, 13, 24, and 27) are identified, each displaying distinct changes in marker gene expression after ASX treatment. This finding suggests a modulation of CD8+ T cell function by ASX. Finally, the key transcription factors for four subclusters of CD8+ T cells are predicted and constructed a cell‐to‐cell communication network based on receptor‐ligand interactions probability. In conclusion, ASX holds the potential to ameliorate liver damage by regulating the number and function of CD8+ T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Wilson's Disease—Crossroads of Genetics, Inflammation and Immunity/Autoimmunity: Clinical and Molecular Issues.
- Author
-
Gromadzka, Grażyna, Czerwińska, Julia, Krzemińska, Elżbieta, Przybyłkowski, Adam, and Litwin, Tomasz
- Subjects
- *
ANTINEUTROPHIL cytoplasmic antibodies , *HEPATOLENTICULAR degeneration , *AUTOIMMUNE hepatitis , *IMMUNOLOGY of inflammation , *SYSTEMIC lupus erythematosus - Abstract
Wilson's disease (WD) is a rare, autosomal recessive disorder of copper metabolism caused by pathogenic mutations in the ATP7B gene. Cellular copper overload is associated with impaired iron metabolism. Oxidative stress, cuproptosis, and ferroptosis are involved in cell death in WD. The clinical picture of WD is variable. Hepatic/neuropsychiatric/other symptoms may manifest in childhood/adulthood and even old age. It has been shown that phenotypic variability may be determined by the type of ATP7B genetic variants as well as the influence of various genetic/epigenetic, environmental, and lifestyle modifiers. In 1976, immunological abnormalities were first described in patients with WD. These included an increase in IgG and IgM levels and a decrease in the percentage of T lymphocytes, as well as a weakening of their bactericidal effect. Over the following years, it was shown that there is a bidirectional relationship between copper and inflammation. Changes in serum cytokine concentrations and the relationship between cytokine gene variants and the clinical course of the disease have been described in WD patients, as well as in animal models of this disease. Data have also been published on the occurrence of antinuclear antibodies (ANAs), antineutrophil cytoplasmic antibodies (ANCAs), anti-muscle-specific tyrosine kinase antibodies, and anti-acetylcholine receptor antibodies, as well as various autoimmune diseases, including systemic lupus erythematosus (SLE), myasthenic syndrome, ulcerative colitis, multiple sclerosis (MS), polyarthritis, and psoriasis after treatment with d-penicillamine (DPA). The occurrence of autoantibodies was also described, the presence of which was not related to the type of treatment or the form of the disease (hepatic vs. neuropsychiatric). The mechanisms responsible for the occurrence of autoantibodies in patients with WD are not known. It has also not been clarified whether they have clinical significance. In some patients, WD was differentiated or coexisted with an autoimmune disease, including autoimmune hepatitis or multiple sclerosis. Various molecular mechanisms may be responsible for immunological abnormalities and/or the inflammatory processes in WD. Their better understanding may be important for explaining the reasons for the diversity of symptoms and the varied course and response to therapy, as well as for the development of new treatment regimens for WD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Severe Liver Damage in an Obese Patient: Onset of Celiac Disease or Overlap Syndrome?
- Author
-
Ghiga, Gabriela, Boca, Laura Otilia, Cojocaru, Elena, Stârcea, Iuliana Magdalena, Țarcă, Elena, Scurtu, Ana Maria, Mocanu, Maria Adriana, Ioniuc, Ileana, Tîrnovanu, Mihaela Camelia, and Trandafir, Laura Mihaela
- Subjects
- *
AUTOIMMUNE hepatitis , *LIVER disease etiology , *GLUTEN-free diet , *LIVER failure , *LIVER diseases , *CELIAC disease - Abstract
Celiac disease (CeD) is an enteropathy caused by the complex interaction between genetic, environmental, and individual immunological factors. Besides the hallmark of intestinal mucosal damage, CeD is a systemic disorder extending beyond the gastrointestinal tract and impacting various other organs, causing extraintestinal and atypical symptoms. The association between CeD and liver damage has been classified into three main categories: mild and asymptomatic liver injury, autoimmune liver injury, and liver failure. We present a case of severe liver damage with cirrhotic evolution in an obese 12-year-old boy who had been admitted due to generalized jaundice and localized abdominal pain in the right hypochondrium. In the course of investigating the etiology of severe liver disease, toxic, infectious, metabolic, obstructive, and genetic causes were excluded. Despite the patient's obesity, a diagnosis of CeD was established, and in accordance with autoimmune hepatitis (AIH) criteria, the patient was diagnosed with autoantibody-negative AIH associated to CeD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. The Impact of Histologic Portal T-Cell Density on the Clinical Outcomes in Hepatic Graft-versus-Host Disease and Autoimmune Liver Diseases.
- Author
-
Lee, Soon Kyu, Park, Sung-Soo, Park, Silvia, Lee, Sung-Eun, Cho, Byung-Sik, Eom, Ki-Seong, Kim, Yoo-Jin, Kim, Hee-Je, Min, Chang-Ki, Cho, Seok-Goo, Lee, Jong Wook, Lee, Seok, Kim, Younghoon, Han, Ji Won, Yang, Hyun, Bae, Si Hyun, Jang, Jeong Won, Choi, Jong Young, Yoon, Seung Kew, and Lee, Dong Yeup
- Subjects
- *
AUTOIMMUNE hepatitis , *GRAFT versus host disease , *HEMATOPOIETIC stem cells , *STEM cell transplantation , *AUTOIMMUNE diseases , *HEPATIC veno-occlusive disease - Abstract
Hepatic graft-versus-host disease (GVHD) significantly impacts morbidity and mortality among allogeneic hematopoietic stem cell transplant recipients. However, the relationship between clinical and immunopathological phenotypes and their influence on clinical outcomes in hepatic GVHD is not well understood. In this study, we aimed to study the implications of portal T-cell infiltration on the clinical outcomes in hepatic GHVD and its similarities to autoimmune liver disease. We analyzed 78 patients with biopsy-confirmed hepatic GVHD (n = 38) or autoimmune liver disease (n = 40) between 2016 and 2021. The cholestatic variant was defined by an R-value < 2.0, based on the ratio of alanine aminotransferase to alkaline phosphatase. The primary outcome was the biochemical response at 4 (early) and 8–12 (late) weeks after corticosteroid treatment. In hepatic GVHD patients, the hepatitic variant (n = 19) showed greater CD3+ T-cell infiltration than the cholestatic variant (n = 19; p < 0.001). No significant differences were observed in the infiltration of CD20+, CD38+, or CD68+ cells. The hepatitic variant had significantly better early and late responses and higher liver-related event-free survival than the cholestatic variants (p < 0.05). Concerning autoimmune liver diseases, the autoimmune hepatitis (AIH) group had significantly more portal T-cell infiltration and better treatment responses than the primary biliary cholangitis (PBC) group. In conclusion, higher portal T-cell infiltration may be associated with better clinical outcomes in patients with hepatic GVHD. Additionally, this study highlights similarities in portal T-cell infiltration and treatment response patterns between AIH and the hepatitic variant, as well as PBC and the cholestatic variant. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Clinical Features, Treatment Challenges And Outcomes Of Patients With Autoimmune Hepatitis: Five Years Experience In Rīga East University Hospital.
- Author
-
Vašuka, Elīna, Novika, Vita, Laivacuma, Sniedze, Krūmiņa, Angelika, and Zeltiņa, Indra
- Subjects
- *
AUTOIMMUNE hepatitis , *CIRRHOSIS of the liver , *LIVER failure , *LIVER diseases , *ELECTRONIC health records , *AZATHIOPRINE - Abstract
Autoimmune hepatitis is an inflammatory disease of the liver of unknown aetiology that can progress to liver cirrhosis and end-stage liver failure. The clinical presentation is often acute hepatitis, but can be insidious or completely asymptomatic. It is characterised by an increase in serum transaminases and immunoglobulin G, an inflammatory liver histology, and the presence of circulating autoantibodies. An autoimmune hepatitis diagnosis justifies lifelong treatment in most patients to prevent the development of cirrhosis and end-stage liver disease. The cornerstone of treatment is steroid induction therapy followed by maintenance therapy with azathioprine, which is effective in most cases. Treatment should be optimised to reach these aims with a minimum of side effects. To achieve optimal results, individual treatment regimens and compromises between treatment aims and personal choices are needed. The aim of the study was to collect data on the clinical course, therapy, and results of autoimmune hepatitis, on the compliance of treatment choice with the criteria for starting therapy. A retrospective cohort study was conducted using data from the Rīga Eastern University Hospital Archives for the period 2019–2023. The study group consisted of 37 patients diagnosed with autoimmune hepatitis who were hospitalised or consulted in an outpatient clinic during the above period. Information relating to the patient's electronic medical records were obtained and no additional sources were used. In the study, it was found that the clinical and diagnostic criteria of autoimmune hepatitis in Rīga Eastern Clinical University Hospital over a five-year period usually correspond to the generally accepted diagnostic principles, but the therapeutic approach does not always correspond to the guidelines, especially regarding the duration of therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. A Rare Case of Bullous Morphea Associated with Autoimmune Hepatitis.
- Author
-
Jokubaitė, Jorinta, Klapatauskaitė, Goda, Macejevska, Monika Marta, and Grigaitienė, Jūratė
- Subjects
- *
AUTOIMMUNE hepatitis , *AUTOIMMUNE diseases , *TREATMENT effectiveness , *RHEUMATOLOGISTS , *DIAGNOSIS , *BULLOUS pemphigoid , *CHRONIC active hepatitis - Abstract
(1) Background: Bullous morphea is an extremely rare form of localized scleroderma, a condition that is marked by the presence of sporadic and intermittent blisters on sclerodermatous skin. This condition stands out due to its rarity and the unique manifestation of blistering, which sets it apart from other forms of localized scleroderma. Due to the infrequent presentation of bullous morphea, there is a significant gap in our understanding of its pathogenesis. The exact mechanisms that lead to the development of this condition remain largely unknown, which poses a challenge for medical professionals in terms of both diagnosis and treatment. The limited number of reported cases makes it difficult to establish a standardized approach to managing this condition, and as a result, treatment options are often limited and may vary from one patient to another. (2) Methods: In this case report, we present a rare case of bullous morphea that manifested before the onset of autoimmune hepatitis. When morphea presents unusually or is resistant to traditional immunosuppressive treatment, a comprehensive assessment of possible concurrent autoimmune illnesses provoking the rash must be conducted. (3) Results: We report a successful case of bullous morphea treated with systemic corticosteroids following a diagnosis of autoimmune hepatitis. (4) Conclusions: This case highlights the importance of considering overlapping autoimmune conditions in the management of bullous morphea and the potential efficacy of systemic corticosteroids in such scenarios. Collaborative efforts involving dermatologists, rheumatologists, and hepatologists are essential to enhance understanding and optimize treatment outcomes for patients affected by this rare and complex condition. Thus, further research is necessary to gain a deeper understanding of the pathogenesis of bullous morphea and to develop more effective and targeted treatment options for patients affected by this condition. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Uncommon toxic epidermal necrolysis -like presentation of cutaneous lupus erythematosus: A series of 6 cases.
- Author
-
Rajagopal, Varun, Bains, Anupama, Kannan, Karthick, Bhardwaj, Abhishek, and Elhence, Poonam
- Subjects
- *
SYSTEMIC lupus erythematosus , *LUPUS erythematosus , *AUTOIMMUNE hemolytic anemia , *AUTOIMMUNE hepatitis , *CONNECTIVE tissue diseases , *TOXIC epidermal necrolysis - Abstract
TEN like Lupus erythematosus is an uncommon life-threatening variant of Lupus erythematosus. It is usually associated with flares of systemic lupus erythematosus and also because of widespread skin erosions, it can cause acute skin failure. It is often confused with drug induced TEN, however the management of both the diseases is different and hence correct diagnosis becomes crucial. In this study we aimed to assess the clinical characteristics and outcome of TEN like LE in the Indian population. All patients satisfying ACR/EULAR 2019 criteria for SLE and clinically diagnosed with TEN like LE were retrospectively reviewed. A total of 6 patients were identified. All patients were female. Except 1 patient who presented de-novo, the others had pre-existing symptoms of connective tissue disease. Half of the patients had palmoplantar involvement. Mucosal involvement was only mild. Majority had systemic involvement in the form of nephritis followed by arthralgia, autoimmune hepatitis and autoimmune hemolytic anemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study.
- Author
-
Fontana, Robert J., Yi Ju Li, Vuppalanchi, Raj, Kleiner, David E., Jiezhun Gu, Shroff, Hersh, Van Wagner, Lisa B., and Watkins, Paul B.
- Subjects
- *
COVID-19 , *AUTOIMMUNE hepatitis , *IMMUNOGLOBULIN G , *HAPLOTYPES , *ANTINUCLEAR factors , *CORONAVIRUS diseases - Abstract
INTRODUCTION: The aim of this study is to describe the presenting features, genetic factors, and outcomes of 23 adults who developed liver injury after coronavirus disease 2019 (COVID-19) mRNA vaccination. METHODS: Patients with suspected COVID-19 vaccine hepatitis were enrolled into the Drug-Induced Liver Injury Network. Causality was assessed using the Drug-Induced Liver Injury Network expert opinion score. High-resolution HLA sequencing was undertaken using Illumina platform. RESULTS: Amongst the 16 high causality cases, median time to onset was 16 days, median age was 63 years, and 75% were female. The injury was hepatocellular in 75% with a median alanine aminotransferase of 497 U/L, and 37% had jaundice. An antinuclear antibody and smooth muscle antibody were detectable in 27% and 36%, but only 12% had an elevated immunoglobulin G level. During follow-up, 37% received a short course of corticosteroids, and 88% fully recovered by 6 months with no deaths observed. HLA alleles associated with autoimmune hepatitis were not overrepresented compared with controls, but an ERAP-2 variant (rs1263907) and the ERAP-1 Hap6 haplotype were significantly overrepresented in the high causality cases vs controls (P = 0.026 and 5 x 10-5, respectively). DISCUSSION: Acute liver injury may arise within 8 weeks of COVID-19 mRNA vaccination that is generally mild and self-limited in most patients. The absence of an association with the AIH HLA alleles combined with the significant ERAP-2 and ERAP-1 Hap6 haplotype associations implicates a unique but very rare host immune response to vaccine-derived antigens in the pathogenesis of COVID-19 vaccine hepatotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Early Graft Loss With Suspected Seventh‐Day Syndrome Following Pediatric Liver Transplantation.
- Author
-
Hartjes, Kayla, Koo, Donna, Al‐Ibraheemi, Alyaa, Sweeny, Katherine F., Wehrman, Andrew, Elisofon, Scott, Lee, Christine K., Cuenca, Alex G., Kim, Heung Bae, and Lee, Eliza J.
- Subjects
- *
LIVER transplantation , *SYNDROMES in children , *LITERATURE reviews , *CHILDREN'S literature , *CLINICAL deterioration - Abstract
Introduction: Allograft dysfunction within the first week posttransplant is an uncommon but known complication following liver transplantation. Seventh‐Day Syndrome (7DS) is a rare complication of allograft dysfunction following liver transplantation characterized by the rapid clinical deterioration of a formerly well‐functioning allograft within the first week posttransplant. The etiology of 7DS is unknown, and treatment options remain limited. While cases of graft survival have been reported, the risk of mortality remains exceedingly high without urgent retransplantation. Methods: Patient data was retrospectively analyzed and a literature review performed. Results: We present a unique case of split liver transplantation into two pediatric recipients in which one recipient developed rapidly progressive graft failure approximately 1 week postoperatively requiring urgent retransplantation while the other recipient had an unremarkable postoperative course. Upon clinical manifestation of progressive graft failure, the patient was treated with thymoglobulin, rituximab, intravenous immunoglobulin, and plasmapheresis. Despite this, the patient's clinical status continued to decline and she underwent retransplantation 11 days following her initial liver transplant. Conclusion: Seventh‐Day Syndrome is a rare complication following liver transplantation that is associated with a high risk of morbidity and mortality. Our case adds to the limited literature on 7DS in children and is the first to report a comparative posttransplant clinical course in two recipients who received split grafts from the same donor. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study.
- Author
-
Plagiannakos, Christina G., Hirschfield, Gideon M., Lytvyak, Ellina, Roberts, Surain B., Ismail, Marwa, Gulamhusein, Aliya F., Selzner, Nazia, Qumosani, Karim M., Worobetz, Lawrence, Hercun, Julian, Vincent, Catherine, Flemming, Jennifer A., Swain, Mark G., Cheung, Angela, Chen, Tianyan, Grbic, Dusanka, Peltekain, Kevork, Mason, Andrew L., Montano-Loza, Aldo J., and Hansen, Bettina E.
- Subjects
- *
AUTOIMMUNE hepatitis , *CHRONIC active hepatitis , *PROPORTIONAL hazards models , *TREATMENT effectiveness , *ALANINE aminotransferase , *ASPARTATE aminotransferase - Abstract
Treatment outcomes for people living with autoimmune hepatitis (AIH) are limited by a lack of specific therapies, as well as limited well-validated prognostic tools and clinical trial endpoints. We sought to identify predictors of outcome for people living with AIH. We evaluated the clinical course of people with AIH across 11 Canadian centres. Biochemical changes were analysed using linear mixed-effect and logistic regression. Clinical outcome was dynamically modelled using time-varying Cox proportional hazard modelling and landmark analysis. In 691 patients (median age 49 years, 75.4% female), with a median follow-up of 6 years (25th-75th percentile, 2.5-11), 118 clinical events occurred. Alanine aminotransferase (ALT) normalisation occurred in 63.8% of the cohort by 12 months. Older age at diagnosis (odd ratio [OR] 1.19, 95% CI 1.06-1.35) and female sex (OR 1.94, 95% CI 1.18-3.19) were associated with ALT normalisation at 6 months, whilst baseline cirrhosis status was associated with reduced chance of normalisation at 12 months (OR 0.52, 95% CI 0.33-0.82). Baseline total bilirubin, aminotransferases, and IgG values, as well as initial prednisone dose, did not predict average ALT reduction. At baseline, older age (hazard ratio [HR] 1.25, 95% CI 1.12-1.40), cirrhosis at diagnosis (HR 3.67, 95% CI 2.48-5.43), and elevated baseline total bilirubin (HR 1.36, 95% CI 1.17-1.58) increased the risk of clinical events. Prolonged elevations in ALT (HR 1.07, 95% CI 1.00-1.13) and aspartate aminotransferase (HR 1.13, 95% CI 1.06-1.21), but not IgG (HR 1.01, 95% CI 0.95-1.07), were associated with higher risk of clinical events. Higher ALT at 6 months was associated with worse clinical event-free survival. In people living with AIH, sustained elevated aminotransferase values, but not IgG, are associated with poorer long-term outcomes. Biochemical response and long-term survival are not associated with starting prednisone dose. Using clinical data from multiple Canadian liver clinics treating autoimmune hepatitis (AIH), we evaluate treatment response and clinical outcomes. For the first time, we apply mixed-effect and time-varying survival statistical methods to rigorously examine treatment response and the impact of fluctuating liver biochemistry on clinical event-free survival. Key to the study impact, our data is 'real-world', represents a diverse population across Canada, and uses continuous measurements over follow-up. Our results challenge the role of IgG as a marker of treatment response and if normalisation of IgG should remain an important part of the definition of biochemical remission. Our analysis further highlights that baseline markers of disease severity may not prognosticate early treatment response. Additionally, the initial prednisone dose may be less relevant for achieving aminotransferase normalisation. This is important for patients and treating clinicians given the relevance and importance of side effects. [Display omitted] • Baseline markers of disease severity and initial prednisone dose do not predict ALT reduction over 18 months in AIH. • Persistent elevations in ALT and AST, but not IgG, are associated with decreased clinical event-free survival in AIH. • Higher ALT at 6 months was associated with worse clinical event-free survival in AIH. • Older age and female sex predict ALT response at 6 and 12 months in AIH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Genetic Mutations Associated With TNFAIP3 (A20) Haploinsufficiency and Their Impact on Inflammatory Diseases.
- Author
-
Bagyinszky, Eva and An, Seong Soo A.
- Subjects
- *
BEHCET'S disease , *AUTOIMMUNE hepatitis , *JUVENILE idiopathic arthritis , *FRAMESHIFT mutation , *AUTOIMMUNE thyroiditis - Abstract
TNF-α-induced protein 3 (TNFAIP3), commonly referred to as A20, is an integral part of the ubiquitin-editing complex that significantly influences immune regulation, apoptosis, and the initiation of diverse immune responses. The A20 protein is characterized by an N-terminal ovarian tumor (OTU) domain and a series of seven zinc finger (ZNF) domains. Mutations in the TNFAIP3 gene are implicated in various immune-related diseases, such as Behçet's disease, polyarticular juvenile idiopathic arthritis, autoimmune thyroiditis, autoimmune hepatitis, and rheumatoid arthritis. These mutations can lead to a spectrum of symptoms, including, but not limited to, recurrent fever, ulcers, rashes, musculoskeletal and gastrointestinal dysfunctions, cardiovascular issues, and respiratory infections. The majority of these mutations are either nonsense (STOP codon) or frameshift mutations, which are typically associated with immune dysfunctions. Nonetheless, missense mutations have also been identified as contributors to these conditions. These genetic alterations may interfere with several biological pathways, notably abnormal NF-κB signaling and dysregulated ubiquitination. Currently, there is no definitive treatment for A20 haploinsufficiency; however, therapeutic strategies can alleviate the symptoms in patients. This review delves into the mutations reported in the TNFAIP3 gene, the clinical progression in affected individuals, potential disease mechanisms, and a brief overview of the available pharmacological interventions for A20 haploinsufficiency. Mandatory genetic testing of the TNFAIP3 gene should be performed in patients diagnosed with autoinflammatory disorders to better understand the genetic underpinnings and guide treatment decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Outcomes and management in paediatric autoimmune hepatitis presenting as acute liver failure: Individual patient data meta‐analysis.
- Author
-
Fawzy, Aly, Sutton, Harry, Vandriel, Shannon M., Sonnenberg, Mikayla, and Kamath, Binita M.
- Subjects
- *
AUTOIMMUNE hepatitis , *LIVER failure , *PEDIATRICS , *LIVER transplantation , *DATABASES - Abstract
Background and Aims: Autoimmune hepatitis (AIH) in children presenting in acute liver failure (ALF) can be fatal and often requires liver transplantation (LTx). This individual patient data meta‐analysis (IPD) aims to examine management and outcomes of this population, given the lack of large cohort studies on paediatric AIH first presenting as ALF (AIH‐ALF). Methods: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta‐Analyses of IPD statement using PubMed and Excerpta Medica dataBASE, and included English studies published between 2000 and 2020. The study included patients under 21 years of age, diagnosed with type 1 or 2 AIH and presenting with ALF. Data extracted included clinical and biochemical characteristics, interventions, and outcomes. Results: Three hundred and thirty eligible patients from 61 studies were identified, with an additional five patients from our institution. The majority were female (66.8%), with a median age of 10. Overall, 59.7% achieved native liver survival (NLS), 35% underwent LTx, and 5% died before LTx. The use of corticosteroids with non‐steroid immunomodulators increased the likelihood of NLS by 2.5‐fold compared to corticosteroids alone. AIH‐1 was associated with 3.3‐fold odds for NLS, compared to AIH‐2. However, on multivariate analysis, only AIH‐1 was identified as an independent predictor for NLS (OR 3.8 [95% CI 1.03–14.2], p =.04). Conclusion: While corticosteroids and non‐steroid immunomodulators treatment may offer enhanced probability of achieving NLS, treatment regimens for AIH‐ALF may need to consider patient‐specific factors, especially AIH type. This highlights the potential for NLS in AIH‐ALF and suggest a need to identify biomarkers which predict the need for combination immunosuppression to avoid LTx. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Simultaneous occurrence of autoimmune hepatitis and autoimmune hemolytic anemia after COVID-19 infection: case report and literature review.
- Author
-
Abe, Ryo, Hasegawa, Naoyuki, Suzuki, Satoshi, Shigeta, Sakiko, Matsuoka, Ryota, Kato, Takayasu, Niisato, Yusuke, Seo, Emiko, Matsubara, Daisuke, and Tsuchiya, Kiichiro
- Abstract
Various autoimmune diseases have been reported to develop as a result of a coronavirus disease 19 (COVID-19) infection. There have been some reports of COVID-19-triggered autoimmune hepatitis and autoimmune hemolytic anemia infection, but none have reported simultaneous onset of these diseases. A 15-year-old girl was admitted to our hospital with severe liver injury and anemia. Three weeks before admission, her father was diagnosed with COVID-19, after which she became aware of a sore throat. Two weeks later, she visited her doctor for malaise. She was referred to our hospital due to severe anemia, elevated hepatobiliary enzymes, and jaundice. A COVID-19 polymerase chain reaction test was positive at the time of referral. She was diagnosed with autoimmune hemolytic anemia based on decreased hemoglobin and haptoglobin, positive direct Coombs test, and increased urinary urobilinogen. Blood tests were positive for antinuclear antibodies, and a liver biopsy revealed interface hepatitis and plasma cell infiltration, consistent with autoimmune hepatitis. Based on these findings, a diagnosis of autoimmune hepatitis and autoimmune hemolytic anemia triggered by COVID-19 infection was made. Steroid therapy was initiated, which resulted in rapid improvement of blood markers and symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER)
- Author
-
Schregel, Ida, Papp, Maria, Sipeki, Nora, Kovats, Patricia J., Taubert, Richard, Engel, Bastian, Campos‐Murguia, Alejandro, Dalekos, George N., Gatselis, Nikolaos, Zachou, Kalliopi, Milkiewicz, Piotr, Janik, Maciej K., Raszeja‐Wyszomirska, Joanna, Ytting, Henriette, Braun, Felix, Casar, Christian, Sebode, Marcial, Lohse, Ansgar W., and Schramm, Christoph
- Subjects
- *
AUTOIMMUNE hepatitis , *IMMUNOGLOBULIN G , *ALANINE aminotransferase , *LIVER diseases , *MULTIVARIATE analysis - Abstract
Background and Aims Methods Results Conclusion The European Reference Network on Hepatological Diseases (ERN RARE‐LIVER) launched the prospective, multicentre, quality‐controlled R‐LIVER registry on rare liver diseases. The aim of this study was to assess the presentation and outcome of autoimmune hepatitis (AIH) after 1 year of treatment.Data were prospectively collected at the time of diagnosis and after 6 and 12 months follow‐up. Complete biochemical response (CBR) was defined as normalization of alanine aminotransferase (ALT) and immunoglobulin G (IgG) serum levels.A total of 231 patients from six European centres were included in the analysis. After 6 months of treatment 50% (106/212), and after 12 months 63% (131/210) of patients reached CBR with only 27% (56/211) achieving a steroid‐free CBR within the first year.Overall, 16 different treatment regimens were administered. Change of treatment, mostly due to intolerance, occurred in 30.4% within the first 6 months. In multivariate analysis, younger age at diagnosis (odds ratio [OR] = 1.03 [95% confidence interval (CI) 1.01–1.05]; p = .007), severe fibrosis (OR .38 [95% .16–.89], p = .026) and change of treatment within the first 6 months (OR .40 [95% CI .2–.86]; p = .018) were associated with a lesser chance of ALT normalization at 12 months follow‐up.The landscape of AIH treatment in Europe is highly heterogeneous, even between expert centres. The results from this first European multicentre prospective registry reveal several unmet needs, highlighted by the overall low rates of CBR and the frequent failure to withdraw corticosteroids. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Associations between modifiable risk factors and hepatocellular carcinoma: a trans-ancestry Mendelian randomization study.
- Author
-
Wei, Xiaoxia, Yang, Chenglei, Lin, Qiuling, Qiu, Moqin, Wen, Qiuping, Zhou, Zihan, Jiang, Yanji, Chen, Peiqin, Liang, Xiumei, Cao, Ji, Tang, Juan, Wei, Yuying, Yu, Hongping, and Liu, Yingchun
- Subjects
- *
HEPATOCELLULAR carcinoma , *EAST Asians , *CHRONIC hepatitis C , *AUTOIMMUNE hepatitis , *ALANINE aminotransferase , *HEPATITIS B , *CHRONIC hepatitis B - Abstract
Background: Potentially modifiable risk factors for hepatocellular carcinoma (HCC) have been investigated in observational epidemiology studies in East Asian and European populations, whereas the causal associations of most of these risk factors remain unclear. Methods: We collected genome-wide association summary statistics of 22 modifiable risk factors in East Asians and 33 risk factors in Europeans. Genetic summary statistics of HCC were sourced from the Biobank Japan study (1,866 cases and 195,745 controls) for East Asians, and the deCODE genetics study (406 cases and 49,302 controls) and the UK Biobank (168 cases and 372 016 controls) for Europeans. Two-sample Mendelian randomization (MR) analyses were performed independently for East Asian and European populations. Results: In East Asians, genetically predicted alcohol frequency, ever drinkers, aspartate aminotransferase (AST), hypothyroidism, chronic hepatitis B, and chronic hepatitis C, metabolic dysfunction-associated steatotic liver disease (MASLD), and autoimmune hepatitis were significantly associated with an increased HCC risk (P < 0.05/22). Among European population, alanine transaminase, AST, MASLD, percent liver fat, and liver iron content were significantly associated with a higher risk of HCC (P < 0.05/33). The replication dataset and meta-analysis further confirmed these results. Conclusions: Although East Asian and European populations have different factors for HCC, their common modifiable risk factors AST and MASLD for HCC, offer valuable insights for targeted intervention strategies to mitigate society burden of HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Pathophysiological features of acute liver failure caused by cholestasis.
- Author
-
Kolosovych, I. V., Hanol, I. V., and Nesteruk, Y. O.
- Subjects
- *
CHRONIC active hepatitis , *LIVER failure , *OBSTRUCTIVE jaundice , *SYSTEMIC inflammatory response syndrome , *HEPATITIS D virus , *AUTOIMMUNE hepatitis ,BILIARY tract cancer - Abstract
Acute liver failure is a syndrome that occurs in 20-59% of patients with liver pathology and is one of the main causes of death in 40% of patients with mechanical jaundice of benign origin and in more than 70% of cases of tumor obstruction of the biliary tract and cancer of caput pancreas. In most cases, the syndrome is a consequence of acute liver damage (viral or drug-induced). Still, it can occur with longterm obstructive jaundice, be the first manifestation of Wilson's disease, autoimmune chronic hepatitis, or superinfection of the hepatitis D virus against the background of chronic hepatitis B. The aim of the work was to study the pathophysiological features of the development of acute liver failure in patients with bile outflow disorders. The pathogenesis of acute liver failure caused by cholestasis is based on the damage and death of hepatocytes due to impaired blood circulation in the liver, as well as the toxic effect on the parenchyma of both the etiological factors themselves and their metabolites. The first week from the onset of symptoms is very important and usually accompanied by a systemic inflammatory response syndrome with significant consequences. At the same time, the main factors influencing the results of treatment of patients at different points in time are the combination of the critical functional reserve of the liver and the nature and severity of liver damage. In the case of the development of a systemic inflammatory response syndrome, there is a further increase in inflammation, which has a systemic nature and leads to the failure of other organs. Under these circumstances, understanding the pathophysiological features of the course of acute liver failure makes it possible to carry out the necessary diagnostic measures on time and offer appropriate therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
42. A case of systemic lupus erythematosus in a patient with Noonan syndrome with recurrent severe hypoglycaemia.
- Author
-
Shotaro Masuoka, Takashi Tanaka, Miwa Kanaji, Karin Furukawa, Keiko Koshiba, Zento Yamada, Eri Watanabe, Mai Kawazoe, Shun Ito, Ayako Fuchigami, and Toshihiro Nanki
- Subjects
- *
AUTOIMMUNE thyroiditis , *SOMATOMEDIN C , *METABOLIC syndrome , *B cell receptors , *AUTOIMMUNE hepatitis , *ANTIPHOSPHOLIPID syndrome - Abstract
This article presents a case study of a patient with Noonan syndrome (NS) who developed systemic lupus erythematosus (SLE) and experienced recurrent severe hypoglycemia. NS is a genetic disorder that can lead to the development of autoimmune diseases, including SLE. The patient in this case exhibited various symptoms of SLE and was successfully treated with glucocorticoids. The article suggests a potential association between NS and autoimmune diseases, but further research is needed to understand the underlying mechanisms. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
43. Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study.
- Author
-
Tanifuji, Ayaka, Ohfuji, Satoko, Matsumoto, Kosuke, Abe, Masanori, Komori, Atsumasa, Takahashi, Atsushi, Kawata, Kazuhito, Sato, Ken, Joshita, Satoru, Umemura, Takeji, Ueno, Masayuki, Nakayama, Nobuaki, Kakisaka, Keisuke, Arinaga‐Hino, Teruko, Ito, Koichi, Kanai, Sachiko, Miura, Ryo, Arizumi, Toshihiko, Asaoka, Yoshinari, and Ito, Takanori
- Subjects
- *
CHOLANGITIS , *SARS-CoV-2 , *COVID-19 vaccines , *VACCINE effectiveness , *BUDD-Chiari syndrome , *AUTOIMMUNE hepatitis - Abstract
Aim: There are few data regarding the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines in patients with intractable hepatobiliary diseases. We conducted a multicenter, questionnaire‐based, cross‐sectional study to determine the safety and effectiveness of the SARS‐CoV‐2 vaccines in Japanese patients with intractable hepatobiliary disease. Methods: Patients aged ≥18 years with autoimmune hepatitis (AIH), primary biliary cholangitis, primary sclerosing cholangitis, Budd–Chiari syndrome, idiopathic portal hypertension, and extrahepatic portal vein obstruction at each center were consecutively invited to join the study. Participants were asked to complete a questionnaire regarding their characteristics, vaccination status, post‐vaccination adverse effects, and SARS‐CoV‐2 infection. Additionally, liver disease status, treatment regimens, and liver function test values pre‐ and post‐vaccination were collected. Results: The survey was conducted from September 2021 to May 2022, and 528 patients (220 AIH, 251 primary biliary cholangitis, 6 AIH– primary biliary cholangitis/primary sclerosing cholangitis overlap, 39 primary sclerosing cholangitis, 4 Budd–Chiari syndrome, 5 idiopathic portal hypertension, and 3 extrahepatic portal vein obstruction) participated in the study. Post‐vaccination adverse effects were comparable to those observed in the general population. Post‐vaccination liver injuries classified as grade 1 or higher were observed in 83 cases (16%), whereas grades 2 and 3 were observed in only six cases (1.1%); AIH‐like liver injury requiring treatment was not observed. Overall, 12 patients (2.3%) were infected with SARS‐CoV‐2, and only one patient was infected 6 months after the second vaccination. Conclusion: SARS‐CoV‐2 vaccines demonstrated satisfactory safety and effectiveness in Japanese patients with intractable hepatobiliary diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Exploring the Pathogenesis of Autoimmune Liver Diseases from the Heterogeneity of Target Cells.
- Author
-
Zi-Xuan Qiu, Lin-Xiang Huang, Xiao-Xiao Wang, Zi-Long Wang, Xiao-He Li, and Bo Feng
- Subjects
INTRAHEPATIC bile ducts ,NATURAL history ,GATA proteins ,BILIARY tract ,LIVER cells ,CHOLANGITIS ,CHRONIC active hepatitis - Published
- 2024
- Full Text
- View/download PDF
45. Comparison of the recommendation of international autoimmune hepatitis pathology group 2022 and the simplified criteria for autoimmune hepatitis 2008: A preliminary study.
- Author
-
Moral, Kenan, Simsek, Berkay, Tomar, Veysel Baran, Albayrak, Cihad, Ergin, Mustafa, Kilic, Guner, Karatas, Ali, Ekmen, Nergiz, Kekilli, Murat, Ibis, Mehmet, Karakan, Tarkan, Cindoruk, Mehmet, Esendagli, Guldal, and Akyol, Gulen
- Subjects
AUTOIMMUNE diseases ,HEPATITIS diagnosis ,HISTOPATHOLOGY ,DRUG side effects ,LIVER injuries - Abstract
Background and Aim: The histological diagnosis of autoimmune hepatitis (AIH) is challenging. A new consensus recommendation was provided by the International AIH Pathology Group to address the problems in the histological diagnosis. The purpose of this study is to compare the 2008 ‘simplified’ criteria for AIH with the ‘consensus recommendation’ of 2022 in terms of diagnostic sensitivity. Materials and Methods: A retrospective analysis was conducted on pathological specimens of patients diagnosed with Autoimmune Hepatitis (AIH) between 2010 and 2022. Out of 188 patients enlisted, 88 were selected based on exclusion criteria. The specimens were examined by two experienced hepatopathologists and a resident pathologist. All specimens were analyzed using both the “simplified” criteria and the new consensus recommendations. Results: Out of a total of 78 patients, the 2022 consensus recommendations raised the diagnostic category of 16 patients (20.5%) to a higher level. Six patients who were previously diagnosed as “atypical” were now considered “possible AIH”, while 10 patients with a “compatible” diagnosis were elevated to “likely AIH” category. No patients were found to fall into a lower diagnostic category according to the new recommendations. A significant difference in diagnostic sensitivity was observed between the 2008 criteria and the 2022 consensus report (p<0.001). Conclusion: The 2022 consensus recommendation may be more sensitive in the diagnosis of AIH in comparison to the 2008 ‘simplified’ histological criteria. More studies are needed both for the validation of the sensitivity of the new consensus recommendation and for the determination of the specificity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Clinical, biochemical and histological features related to treatment response and prognosis in autoimmune hepatitis.
- Author
-
Resende Guedes, Ludmila, Lopes Cançado, Guilherme Grossi, Campos Santo, Bruno, dos Santos Jacomassi, Luma, Jorge Nardelli, Mateus, Farage Osório, Fernanda Maria, Costa Faria, Luciana, and Alves Couto, Cláudia
- Subjects
AUTOIMMUNE hepatitis ,CHRONIC active hepatitis ,PROGNOSIS ,ALANINE aminotransferase ,OVERALL survival ,LIVER transplantation - Abstract
Introduction and Objectives: Autoimmune hepatitis (AIH) is a rare disease with a complex and not fully understood pathogenesis. Prognostic factors that might influence treatment response, relapse rates, and transplant-free survival are not well established. This study investigates clinical and biochemical markers associated with response to immunosuppression in patients with AIH. Materials and Methods: This retrospective cohort study included 102 patients with AIH treated with immunosuppressants and followed at the Federal University of Minas Gerais, Brazil, from 1990 to 2018. Pretreatment data such as clinical profiles, laboratory, and histological exams were analyzed regarding biochemical response at one year, histological remission, relapse, and death/transplantation rates. Results: Cirrhosis was present in 59 % of cases at diagnosis. One-year biochemical remission was observed in 55.7 % of the patients and was found to be a protective factor for liver transplant. Overall survival was 89 %. Patients with ascites at disease onset showed a higher aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) ratio and elevated Model of end-stage liver disease (MELD) score. The presence of ascites was significantly associated with a 20-fold increase in mortality rate. Conclusions: AIH has a severe clinical phenotype in Brazilians, with high rates of cirrhosis and low remission rates. Early diagnosis and treatment are essential for achieving remission and reducing complications. The presence of ascites is significantly associated with mortality, emphasizing the importance of monitoring and prompt intervention. This study also stresses the need for further research on AIH in Latin America. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Lymphocyte metabolism and the level of circulatory cytokines in children with autoimmune disease
- Author
-
T. V. Radygina, O. V. Kurbatova, D. G. Kuptsova, S. V. Petrichuk, A. P. Fisenko, G. B. Movsisyan, L. M. Abdullaeva, A. S. Potapov, N. N. Murashkin, and D. V. Parakhina
- Subjects
dehydrogenases ,th17 lymphocytes ,tregs ,glycolysis ,cytokines ,inflammatory bowel diseases ,multiple sclerosis ,psoriasis ,autoimmune hepatitis ,children ,Immunologic diseases. Allergy ,RC581-607 - Abstract
In recent decades, there has been an increase in the incidence of autoimmune diseases (AID) among adults and children. The immunopathogenesis of AID is based on an imbalance between autoaggressive and regulatory cells (Tregs), which is regulated by metabolic signaling pathways and the cytokine microenvironment. Understanding the mechanisms of immunometabolism opens up new possibilities for the treatment of patients with AID. The aim was to evaluate the activity of lymphocyte dehydrogenases associated with OXPHOS and glycolysis, depending on the level of proinflammatory and anti-inflammatory cytokines in children with AID.324 children with AID were examined: 80 – Crohn’s disease (CD), 53 – ulcerative colitis (UC), 89 – psoriasis (PS), 66 – multiple sclerosis (MS), 36 – autoimmune hepatitis (AIH). Activity of mitochondrial dehydrogenases (succinate dehydrogenase (SDH) and glycerol-3-phosphate dehydrogenase (GFDH)) were evaluated by immunocytochemical method using flow cytometry. The level of cytokines (CС) in blood sera was determined by multiplex analysis.In each studied group of children, CС with the highest values in exacerbation and remission of the disease were identified. The maximum values of CС were in patients with exacerbation: CD, UC, PS, MS – IL-23; AIH – IL-27. Evaluation of cytokine complexes associated with cells showed significant differences between patients in exacerbation/remission: CD, UC and PS – M1(IL-1+IL-6+TNFα), cTh1(IFNγ+IL-12p70+TNFβ+IL-2), cTh2 (IL-4+IL-5+IL-10+IL-13+IL-17E/IL-25+IL-33), cTh17 (IL-1β+IL-6+IL-17A+IL-17F+IL-21+IL-22+IL-23); MS – M1, cTh1, cTh2; AIH – cTh2. SDH activity in AID remission differed between pathologies in CD4+ cells, Th17 and Tregs. In exacerbation of AID, there were differences in Tregs between patients with UC and PS. The highest GPDH activity in exacerbation was observed in CD4+ lymphocytes, Th17 and Tregs in CD. The ratio of SDH/GPDH in T-lymphocytes in children with CD in exacerbation and remission was lowest and significantly lower than in UC, PS, MS, AIH and apparently healthy children. In the group of children with a low SDH/GPDH ratio, the levels of CCL20/MIP3α, IFNγ, IL-12p70, IL-13, IL-17A, IL-1β, and TNFα were significantly increased. Conclusions. Informative cytokine complexes were identified in children with AID. The relationship between the metabolic activity of lymphocytes and the level of circulating cytokines is shown.
- Published
- 2024
- Full Text
- View/download PDF
48. Metabolic Reprogramming of CD4+ T Cells by Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuates Autoimmune Hepatitis Through Mitochondrial Protein Transfer
- Author
-
Shen M, Zhou L, Fan X, Wu R, Liu S, Deng Q, Zheng Y, Liu J, and Yang L
- Subjects
autoimmune hepatitis ,extracellular vesicles ,metabolic reprogramming ,mitochondria ,inflammation ,Medicine (General) ,R5-920 - Abstract
Mengyi Shen,1,* Leyu Zhou,1,* Xiaoli Fan,1 Ruiqi Wu,1 Shuyun Liu,2 Qiaoyu Deng,1 Yanyi Zheng,1 Jingping Liu,2 Li Yang1 1Department of Gastroenterology and Hepatology and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2NHC Key Laboratory of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li Yang; Jingping Liu, Email yangli_hx@scu.edu.cn; liujingping@scu.edu.cnBackground: Autoimmune hepatitis (AIH) is a serious liver disease characterized by immune disorders, particularly effector T-cell overactivation. This study aimed to explore the therapeutic effect and underlying mechanism of mesenchymal stem cell-derived extracellular vesicle (MSC-EV) treatment on CD4+ T-cell overactivation and liver injury in AIH.Methods: The metabolic changes of CD4+ T cells were assayed in human AIH and mouse hepatitis models. The liver protective effect of MSC-EVs was evaluated by transaminase levels, liver histopathology and inflammation. The effect of MSC-EVs on the metabolic state of CD4+ T cells was also explored.Results: Enhanced glycolysis (eg, ~1.5-fold increase in hexokinase 2 levels) was detected in the CD4+ T cells of AIH patient samples and mouse hepatitis models, whereas the inhibition of glycolysis decreased CD4+ T-cell activation (~1.8-fold decrease in CD69 levels) and AIH liver injury (~6-fold decrease in aminotransferase levels). MSC-EV treatment reduced CD4+ T-cell activation (~1.5-fold decrease in CD69 levels) and cytokine release (~5-fold decrease in IFN-γ levels) by reducing glycolysis (~3-fold decrease) while enhancing mitochondrial oxidative phosphorylation (~2-fold increase in maximal respiration) in such cells. The degree of liver damage in AIH mice was ameliorated after MSC-EV treatment (~5-fold decrease in aminotransferase levels). MSC-EVs carried abundant mitochondrial proteins and might transfer them to metabolically reprogram CD4+ T cells, whereas disrupting mitochondrial transfer impaired the therapeutic potency of MSC-EVs in activated CD4+ T cells.Conclusion: Disordered glucose metabolism promotes CD4+ T-cell activation and associated inflammatory liver injury in AIH models, which can be reversed by MSC-EV therapy, and this effect is at least partially dependent on EV-mediated mitochondrial protein transfer between cells. This study highlights that MSC-EV therapy may represent a new avenue for treating autoimmune diseases such as AIH.Keywords: autoimmune hepatitis, extracellular vesicles, metabolic reprogramming, mitochondria, inflammation
- Published
- 2024
49. Systemic Lupus Erythematosus with Massive Splenomegaly: A Case Report
- Author
-
P. Singhal, A. Pandey, S. M. Sindagi, H. Singh, M. Negi, and P. Bansal
- Subjects
massive splenomegaly ,systemic lupus erythematosus ,autoimmune hepatitis ,lupus hepatitis ,lupoid hepatitis ,Medicine - Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect any organ system in the body. It may also be complicated by other autoimmune diseases. This case report describes a patient who presented with massive splenomegaly on a background of clinical features of SLE. Splenomegaly in SLE however, is not common. The patient was evaluated further for haematological complications and liver involvement. She was diagnosed to have SLE-Autoimmune hepatitis overlap. SLE-AIH overlap syndrome is rare, but specific diagnosis is important because it influences the choice of immune-suppressants as well as long-term outcome. Liver biopsy helps clinch the diagnosis and should be encourage early in the diagnostic plan. It is also important to differentiate between the various causes of liver involvement in SLE.
- Published
- 2024
- Full Text
- View/download PDF
50. A case report on acquired ichthyosis and autoimmune hepatitis
- Author
-
Annaërolande Charles, Angie Ossa, Sophia Echevarria, Mary Hughes, Mohammad Manzoor, Zafar Qureshi, Orien Tulp, and Syed Rizvi
- Subjects
ichthyosis ,autoimmune hepatitis ,liver disease ,Medicine - Abstract
Background and Objectives: Juvenile autoimmune hepatitis (AIH) is an inflammatory, immune-mediated liver disease that affects individuals from infancy to adolescence. The clinical presentation of AIH can mimic other hepatic disorders, such as viral hepatitis, toxic hepatitis, and Wilson's disease, often manifesting with symptoms like fatigue, nausea, vomiting, jaundice, fever, and pruritus.Case Presentation: A 16-year-old male with a history of congenital ichthyosis, xerosis cutis, mild intermittent asthma, and environmental allergic rhinitis presented to the clinic with upper respiratory symptoms. Upon examination, the patient was found to be jaundiced, prompting an urgent referral for further evaluation. This led to a diagnosis of autoimmune hepatitis and inflammatory bowel disease.Discussion: Juvenile autoimmune hepatitis is a rare but serious inflammatory liver disorder that primarily affects infants and adolescents. Due to its similarities with various other liver diseases, differential diagnosis can be quite challenging. Overall, the prognosis for our patient appears to be positive.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.